rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter

Overview

The study aims at clarifying (in a randomized, double-blinded design): 1. Whether stimulation with 0.1 mg rhTSH 24, 48 or 72 hours before induction of a 131I-tracer dosis increases the 131I uptake in patients with atoxic multinodular goitre and to study which time interval is the most optimal (Part I) 2. Whether patients suffering from atoxic multinodular goitre obtains a corresponding goitre reduction compared with a control group when stimulating with 0.1 mg rh TSH 24, 48 or 72 hours before 131I therapy and when reducing the thyroid radiation dose to 50 Gy (Part II) The two studies will be carried out successively on the same patient population. The 131I uptake will be carried out first followed by the I therapy itself. The patients are compared with a placebo-treated control group going through the same course of treatment, but the 131I dosis will be 100 Gy (standard treatment). After the 131I therapy, all patients are followed during one year with a regular ultrasound scan of the thyroid gland and control of the metabolic status. The patient satisfaction is monitored by the use of a visual-analogue-scale.

Full Title of Study: “The Effect of 0.1 mg Recombinant Human Thyrotropin (rhTSH) on Thyroid Radioiodine-uptake and the Degree of Goiter Reduction Following 131I-therapy, in Patients With Benign Non-toxic Nodular Goiter. A Randomized, Double-blind, Placebo-controlled Trial.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: April 2009

Interventions

  • Drug: Recombinant human thyrotropin (Thyrogen)
    • 0.1 mg rhTSH administered intramuscularly
  • Drug: recombinant human TSH
    • 0.1 mg rhTSH administered intramuscularly
  • Other: isotonic saline = placebo
    • 0.1 mg isotonic saline injected intramuscularly

Arms, Groups and Cohorts

  • Active Comparator: rhTSH
    • proceeded by 0.1 mg rhTSH
  • Placebo Comparator: Placebo
    • 1 ml isotonic saline

Clinical Trial Outcome Measures

Primary Measures

  • An intra-individual comparison of the thyroid 131I-uptake before and after stimulation with rhTSH /placebo
    • Time Frame: 24 and 96 hours after tracer administration
  • An inter-individual comparison of the thyroid 131I uptake between those who receive placebo and those who receive rhTSH
    • Time Frame: 24 and 96 hours after tracer administration
  • An estimation of which time-interval, injecting rhTSH, that is more favourable before 131I therapy (24 hours, 48 hours or 72 hours)
    • Time Frame: 24 and 96 hours after tracer administration
  • A comparison of the degree of goiter reduction when patients are prestimulated with rhTSH and receive a thyroid 131I dose of 50 Gy or when receiving conventional 131I, receiving a thyroid dose of 100 Gy
    • Time Frame: 3, 6, 9 and 12 months after 131I therapy

Secondary Measures

  • A registration of adverse effects following rhTSH/placebo
    • Time Frame: All adverse effects occuring within one year follow-up
  • Patient satisfaction (Visual Analogue Scale) before, 3 months post 131I therapy, and at the end of follow-up (1 year).
    • Time Frame: baseline, 3 and 12 months after 131I therapy
  • Development of TPOab or TSHRab
    • Time Frame: At 12 months follow-up
  • Thyroid function
    • Time Frame: At 12 months follow up.

Participating in This Clinical Trial

Inclusion Criteria

  • Age over 18 years – Apart from benign non-toxic goiter no other serious illness – Signed proof of participation Exclusion Criteria:

  • Treatment with Levothyroxine – Former 131I-therapy – A thyroid volume above 100 ml or a retro-clavicular component – Unsafe contraception – Pregnancy or breastfeeding – Participation in another clinical trial – Previous allergic reaction toward rhTSH – Suspicion of malignancy in the thyroid gland either by clinical examination, laboratory findings (a raised serum calcitonin or ionized calcium)or by fine-needle aspiration biopsy – Physically or mental condition making it impossible to participate – Acute ischemic heart attach within the last 3 months – Alcohol and/or drug addicts

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Steen Bonnema
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Steen Bonnema, Consultant, phd, DMsc – Odense University Hospital
  • Overall Official(s)
    • Steen J. Bonnema, MD, Principal Investigator, Odense University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.